HK1200447A1 - -吡咯並 吡啶衍生物及它們作為激酶抑制劑的用途 - Google Patents

-吡咯並 吡啶衍生物及它們作為激酶抑制劑的用途

Info

Publication number
HK1200447A1
HK1200447A1 HK15100794.1A HK15100794A HK1200447A1 HK 1200447 A1 HK1200447 A1 HK 1200447A1 HK 15100794 A HK15100794 A HK 15100794A HK 1200447 A1 HK1200447 A1 HK 1200447A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolo
kinase inhibitors
pyridine derivatives
pyridine
derivatives
Prior art date
Application number
HK15100794.1A
Other languages
English (en)
Inventor
斯蒂芬．斯托克斯
克里斯多佛．約翰．格雷厄姆
斯圖亞特．克里斯多佛．雷
艾瑪．杰妮．斯蒂芬尼亞克
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of HK1200447A1 publication Critical patent/HK1200447A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15100794.1A 2012-01-30 2015-01-23 -吡咯並 吡啶衍生物及它們作為激酶抑制劑的用途 HK1200447A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1201566.5A GB201201566D0 (en) 2012-01-30 2012-01-30 New chemical compounds
PCT/GB2013/050212 WO2013114113A1 (en) 2012-01-30 2013-01-30 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1200447A1 true HK1200447A1 (zh) 2015-08-07

Family

ID=45876325

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100794.1A HK1200447A1 (zh) 2012-01-30 2015-01-23 -吡咯並 吡啶衍生物及它們作為激酶抑制劑的用途

Country Status (21)

Country Link
US (3) US10000481B2 (zh)
EP (1) EP2809670B1 (zh)
JP (1) JP6199316B2 (zh)
CN (4) CN106866658B (zh)
AU (1) AU2013213954B2 (zh)
BR (1) BR112014018795B1 (zh)
CA (1) CA2862940C (zh)
DK (1) DK2809670T3 (zh)
EA (1) EA026657B1 (zh)
ES (1) ES2637340T3 (zh)
GB (1) GB201201566D0 (zh)
HK (1) HK1200447A1 (zh)
HU (1) HUE035332T2 (zh)
IL (1) IL233595B (zh)
IN (1) IN2014DN06104A (zh)
MX (1) MX352927B (zh)
NZ (1) NZ627361A (zh)
PL (1) PL2809670T3 (zh)
PT (1) PT2809670T (zh)
WO (1) WO2013114113A1 (zh)
ZA (1) ZA201405070B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
MY168958A (en) * 2012-04-23 2019-01-28 Genentech Inc Intermediates and processes for preparing compounds
EP3036227B1 (en) * 2013-08-22 2020-01-08 Genentech, Inc. Process for preparing a compound
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US10032914B2 (en) * 2015-10-20 2018-07-24 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device and manufacturing method thereof
AU2017222908B2 (en) 2016-02-23 2021-02-04 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN116261452A (zh) * 2020-07-15 2023-06-13 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
CN116157394A (zh) 2020-07-15 2023-05-23 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
TW202216685A (zh) * 2020-07-15 2022-05-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
WO2023137034A1 (en) * 2022-01-12 2023-07-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012976A (en) * 1909-03-25 1911-12-26 Adolf Bordt Adding-machine.
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
CN102786482A (zh) * 2003-11-21 2012-11-21 阿雷生物药品公司 Akt蛋白激酶抑制剂
WO2009089352A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
ES2461799T3 (es) * 2008-01-22 2014-05-21 Vernalis (R&D) Ltd. Derivados de indolil-piridona que tienen actividad inhibidora de la quinasa de control 1
AR071717A1 (es) * 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
WO2009151589A1 (en) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use
MX2012001419A (es) * 2009-08-06 2012-03-16 Merck Patent Gmbh Compuestos biciclicos novedosos de urea.
US9290499B2 (en) * 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds

Also Published As

Publication number Publication date
ES2637340T3 (es) 2017-10-11
US20180362526A1 (en) 2018-12-20
EA026657B1 (ru) 2017-05-31
PT2809670T (pt) 2017-08-23
BR112014018795B1 (pt) 2020-09-29
AU2013213954A1 (en) 2014-08-07
NZ627361A (en) 2016-07-29
MX352927B (es) 2017-12-14
CN107011341A (zh) 2017-08-04
US10000481B2 (en) 2018-06-19
IN2014DN06104A (zh) 2015-08-14
US20210206762A1 (en) 2021-07-08
MX2014009112A (es) 2014-11-10
DK2809670T3 (en) 2017-08-28
US10889582B2 (en) 2021-01-12
CN104203948A (zh) 2014-12-10
EA201491376A1 (ru) 2015-01-30
HUE035332T2 (en) 2018-05-02
CN106866658A (zh) 2017-06-20
EP2809670A1 (en) 2014-12-10
BR112014018795A2 (pt) 2017-07-04
IL233595B (en) 2018-05-31
CA2862940C (en) 2021-09-14
ZA201405070B (en) 2016-03-30
IL233595A0 (en) 2014-08-31
JP2015505555A (ja) 2015-02-23
JP6199316B2 (ja) 2017-09-20
PL2809670T3 (pl) 2017-10-31
US20150011533A1 (en) 2015-01-08
CN106866658B (zh) 2021-04-27
AU2013213954B2 (en) 2016-02-25
CA2862940A1 (en) 2013-08-08
CN111484493A (zh) 2020-08-04
WO2013114113A1 (en) 2013-08-08
EP2809670B1 (en) 2017-05-17
GB201201566D0 (en) 2012-03-14

Similar Documents

Publication Publication Date Title
HRP20171724T1 (hr) Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze
HK1200447A1 (zh) -吡咯並 吡啶衍生物及它們作為激酶抑制劑的用途
EP2931722A4 (en) SUBSTITUTED 1H-PYRROLO- [2,3-B] PYRIDINE AND 1H-PYRAZOLO- [3,4-B] PYRIDINE DERIVATIVES AS SALT-INDUCIBLE KINASE-2 (SIK2) INHIBITORS
HK1222659A1 (zh) 吡咯並 嘧啶衍生物，它們的製備方法和它們作爲激酶抑制劑的用途
IL235819A0 (en) Preparation of pyrrolo[b–3,2]pyridines
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
AP2014007899A0 (en) 2-Amino, 6-phenyl substituted pyrido [2,3-D] pyrimidine derivatives useful as RAF kinase inhibitors
PT2812337T (pt) Derivados de furo[3,2-b]piridina como inibidores de tbk1 e ikk
IL232717A0 (en) 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives
EP2970278A4 (en) Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9-
ZA201307511B (en) Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses
SG11201408816QA (en) 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
EP2922543A4 (en) SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS
ZA201307085B (en) Thieno [2,3-d] pyrimidine derivatives and their use to treat arrhythmia
EP2835372A4 (en) THIOPHENE [2, 3-D] PYRIMIDINE DERIVATIVE AND METHOD OF PREPARATION AND USE
SG11201500883YA (en) 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
PL390846A1 (pl) Pochodne 5,11-dimetylo-5H-indolo[2,3-b]chinoliny